Clinical trials: Vascular Risk
Disbiosis, Obesity
Limosilactobacillus Fermentum CRL 1446 - CONICET CASASCO
This research study aims to determine if a probiotic called Limosilactobacillus fermentum CRL 1446 can improve the health of people at risk for cardiovascular disease.
- Conditions
- Disbiosis, Obesity, Overweight (BMI > 25), Hypertension (Without Type 2 Diabetes Mellitus)
- Trial name
- NCT07530575
- Testing
- Limosilactobacillus fermentum 1446 CRL CONICET 2.20E+9 CFU
- Where
- 2 sites in Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- PINER Pastor Manfredi Winery
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Embolism
Crux Biomedical Vena Cava Filter Study - United States
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 2 (NCT01120509)
- Testing
- Inferior Vena Cava Filter
- Where
- 17 sites in United States
- Volunteers
- 88 people
- Sponsor
- Crux Biomedical
Stable Coronary Artery Disease (CAD), Myocardial Infarction
Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients
THis study is intended to provide contemporary data on the burden of disease in patients 1 to 3 years post-MI, including a description of patient characteristics, current treatment patterns, rate of major CV events, and…
- Trial name
- TIGRIS (NCT01866904)
- Where
- 309 sites in United States, Argentina and 23 more
- Volunteers
- 9,284 people
- Sponsor
- AstraZeneca
High Risk Cardiovascular Disease, Hypertension
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events.
- Conditions
- High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
- Trial name
- ZENITH (NCT07181109)
- Testing
- Zilebesiran
- Where
- 1,190 sites in United States, Argentina and 33 more
- Volunteers
- 11,000 people
- Sponsor
- Alnylam Pharmaceuticals
Atherosclerotic Cardiovascular Disease
A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Spain)
This study will evaluate cardiovascular outcomes among individuals with clinically established atherosclerotic cardiovascular disease (ASCVD) who have not previously experienced a myocardial infarction (MI) or ischemic stroke.
- Trial name
- NCT07905534
- Where
- Spain
- Volunteers
- 18,000 people
- Sponsor
- Sanofi
CAD - Coronary Artery Disease
REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care
REFINE-CAC is a prospective, multi-center trial assessing the management of asymptomatic participants with CAC scores 1-299 Agatston units or incidental CAC findings on chest computed tomography (CT), all of whom will undergo…
- Trial name
- REFINE-CAC (NCT07853716)
- Testing
- Heartflow Analysis
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- HeartFlow, Inc.
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST 2 (NCT00442325)
- Testing
- Atorvastatin (Lipitor)
- Where
- 32 sites in Greece, Hungary and 6 more
- Volunteers
- 595 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Carotid Artery Diseases
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
The objective of this study is to evaluate acute device and technical success of the CGuard Prime™ Carotid Stent System (80cm) when used in conjunction with the Enroute NPS during Transcarotid Artery Revascularization procedures…
- Trial name
- NCT06653387
- Testing
- CGuard Prime 80cm stent system
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- InspireMD
Shock, Cardiogenic, High Risk Percutaneous Coronary Interventions
Synchronized Cardiac Assist for Cardiogenic Shock
The purpose of this study is to collect prospective safety and performance information for the i-COR® device using synchronized cardiac assist in the setting of combined heart-lung failure or in high risk percutaneous…
- Trial name
- NCT02697006
- Testing
- i-cor Synchronized Cardiac Assist Device
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Xenios AG
Compartment Syndrome
Assessment of Near Infrared Spectroscopy as a Diagnostic Tool in Acute Compartment Syndrome
The purpose of this study is to define the reliability and accuracy of Near Infrared Spectroscopy (NIRS) in the detection of intra-compartmental tissue perfusion in injured and noninjured extremities over time.
- Trial name
- NCT01077934
- Testing
- near-infrared spectroscopy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- J&M Shuler
Coronary Artery Disease, Stable Angina Pectoris
A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT
The objective of this study is a comparative evaluation of BuMA Supreme™ stent and of Xience V/Prime stent in terms of the extent of neointima formation at 1 or 2 months after implanting in relatively high bleeding risk patients…
- Conditions
- Coronary Artery Disease, Stable Angina Pectoris, Unstable Angina Pectoris
- Trial name
- NCT02747329
- Testing
- BuMA Supreme™ stent, Xience V/Prime stent
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Cardiothoracic Surgery, Vascular Surgery
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery
This study will evaluate the safety and efficacy of ABT-719 in patients undergoing high risk major surgery.
- Trial name
- NCT01897519
- Testing
- ABT-719
- Where
- 23 sites in United States, Denmark
- Volunteers
- 56 people
- Sponsor
- AbbVie
Multiple Myeloma
Combination Study for High Risk Multiple Myeloma Patients
Despite the recent introduction of novel anti-multiple myeloma (MM) agents, high risk MM remains with poor prognosis and a therapeutic challenge.
- Trial name
- NCT03104270
- Testing
- Elotuzumab, Pomalidomide, Carfilzomib
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Oncotherapeutics
Carotid Artery Plaque, Arteriosclerosis
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
Objectives: Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) Secondary: To…
- Conditions
- Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
- Trial name
- AUDITOR (NCT00228176)
- Testing
- Rimonabant
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Sanofi
Pulmonary Embolism, Deep Vein Thrombosis
The Angel® Catheter Pivotal Clinical Trial
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
- Trial name
- NCT02186223
- Testing
- The Angel® Catheter
- Where
- 21 sites in United States
- Volunteers
- 172 people
- Sponsor
- BiO2 Medical
Hypercholesterolemia, Cardiovascular Risk Factor
Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk
This clinical study aims to assess the efficacy of 6 weeks 2.5g dose of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism and cardiovascular health in individuals at increased cardio-metabolic risk.
- Conditions
- Hypercholesterolemia, Cardiovascular Risk Factor, Dyslipidemias, Atherosclerosis
- Trial name
- OLALIP (NCT05594979)
- Testing
- TOTUM-070
- Where
- France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Cardiovascular Disease
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established…
- Trial name
- AZURE-Outcomes (NCT07000357)
- Testing
- AZD0780
- Where
- 1,452 sites in United States, Argentina and 34 more
- Volunteers
- 15,100 people
- Sponsor
- AstraZeneca
Cardiogenic Shock, High Risk PCI
Impella Real-World Surveillance of Patients Using Sodium Bicarbonate
The population enrolled in this study are all subjects who received an Impella in which a bicarbonate-based purge solution was used.
- Trial name
- NCT05820451
- Testing
- Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution, Impella RP with Sodium Bicarbonate used as purge solution
- Where
- 20 sites in United States
- Volunteers
- 312 people
- Sponsor
- Abiomed Inc.
Elevated Cardiac Risk, Coronary Arteries Disease Risk
Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery
The Primary Objective is to show non inferiority in cardiac safety (i.e myocardial necrosis-MN- assessed by positive cardiac Troponin I -cTnI- ultrasensitive assay) of a Xenon based general anesthesia procedure in patients with…
- Trial name
- CARVASAXe (NCT01120405)
- Testing
- Xenon, Sevoflurane
- Where
- 13 sites in France
- Volunteers
- 600 people
- Sponsor
- Air Liquide Santé International